Health Care

Founder sells 462 SciSparc shares at $10, above market $8.73, amid 85% YTD drop—what it signals for the biotech’s future.

Kymera CFO’s insider buy signals confidence in the company’s clinical pipeline and potential rebound, hinting at strong future growth for investors.

Coherus CFO’s 225k option sale shows insider confidence, ties to new $1.59 exercise price and biosimilar growth—an insight for investors and industry analysts.

Insider buying shows confidence in CERUS’s pathogen‑inactivation platform, with RSU purchases by top executives suggesting future upside despite current volatility.

Insightful insider buying by Mirum Pharmaceuticals’ director hints at a soon‑to‑come milestone in its cholestatic liver‑disease pipeline, boosting investor confidence amid strong market fundamentals and favorable regulatory trends.

OKYO Pharma insiders hold long‑term options, signaling confidence in future growth while signaling potential dilution – a strategic view that could shape investors’ outlook as the company advances its pre‑clinical pipeline and seeks financing.

Axsome insider sale: senior director Coleman Mark sells 6 000 shares at ~$233, a disciplined 10b‑5 plan that signals confidence, not a bearish signal, amid strong pipeline growth.

DIANTHUS THERAPEUTICS insider buys: R&D EVP’s 27 k shares signal confidence amid 353% YTD gains and Phase III data‑driven growth potential.

Insider buy at PAHC signals confidence amid regulatory easing & dividend allure—discover why this animal‑health stock could boost long‑term value.

NovaBridge insider buying signals confidence amid a 28% decline: senior VP Xu Cong Claire’s purchase may hint at upcoming clinical milestones and potential upside.